Whalesbook
Neogen Chemicals has disclosed that its promoter, Dr. Harin Haridas Kanani, pledged 20,19,167 equity shares on April 13, 2026. This represents 7.65% of the company's diluted share capital and serves as collateral for a loan obtained by Cadamba Solutions Private Limited, an entity within the promoter group, from Avendus Structured Credit Fund III.
The disclosure of this pledge on April 29, 2026, follows a recent communication from the BSE dated April 27, 2026. The exchange had flagged a 'Discrepancy in disclosure' concerning SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, raising questions about past compliance.
Share pledges by promoters can signal increased leverage for the promoter group. For Neogen Chemicals, this means a significant portion of Dr. Kanani's stake is now tied to Cadamba Solutions' debt. Investors will be closely watching the financial health and borrowing capacity of Cadamba Solutions. Key risks include potential regulatory scrutiny or penalties stemming from the disclosure discrepancy, and the possibility that the lender could invoke the pledged shares if Cadamba defaults on its loan, potentially altering Neogen's promoter shareholding.
Neogen Chemicals is a notable Indian manufacturer specializing in custom synthesis and contract manufacturing for the pharmaceutical and agrochemical industries. Prior to this pledge, Dr. Harin Haridas Kanani held a total of 33,38,250 shares, representing 12.65% of the company's diluted capital.
Investors will likely focus on the company's plans to clarify and resolve the disclosure discrepancy flagged by the BSE, as well as the financial performance of Cadamba Solutions and any actions by Avendus Structured Credit Fund III.